Amgen announced on April 22, 2026 that David M. Reese, Executive Vice President and Chief Technology Officer, is retiring effective June 30, 2026.

1. 01

   Amgen announced on April 22, 2026 that David M. Reese, Executive Vice President and Chief Technology Officer, is retiring effective June 30, 2026.

2. 02

   The company said it will redistribute the responsibilities of Reese's role to James E. Bradner, Murdo Gordon and Peter H. Griffith effective June 1, 2026 to further integrate science, technology and data.

3. 03

   Amgen said that effective June 1, 2026, Bradner will serve as Executive Vice President, Research and Development, Artificial Intelligence and Data, Sean Bruich will serve as Senior Vice President, Chief Technology Officer, and Gordon will serve as Executive Vice President, Amgen Global Markets and Policy.

4. 04

   The company said Reese will remain employed as an Executive Vice President until his retirement on June 30, 2026, at which time he will be retirement eligible under the company's plans and policies and will receive retirement benefits. It added that he joined the company in 2005 and served as executive vice president of Research and Development from 2018 to 2023.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.